Skip to main content
    N

    Neurocrine Biosciences Inc (NBIX)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $164.63
    +4.87 (+3.05%)

    Market Cap: $16.17B

    Last updated: Nov 06, 2026 at 4:27 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    45%(18/40)
    Avg Surprise
    -6.84%
    Streak
    3 Q

    Upcoming Estimates

    Period ending Dec 31, 2026
    EPS Consensus$3.80
    Range$2.54 - $4.96
    17 analysts
    Revenue Consensus
    $1.2B
    Range$1.1B - $1.4B
    26 analysts
    Last 12 of 40 reported quarters and 1 upcoming estimate
    PeriodReportedEst.RangeSurpriseB/MAnalystsRevisionsYoY
    Dec 26EST
    		-$3.80$2.54 - $4.96--17--
    Sep 26
    Reported Nov 2
    		$2.78$1.95$1.27 - $2.53+42.56%Beat17
    1
    1
    30d
    		+28.1%
    Jun 26
    Reported Jul 30
    		$2.36$1.88$-1.90 - $3.16+25.53%Beat15
    2
    1
    30d
    		+43.0%
    Mar 26
    Reported May 5
    		$1.94$1.70$1.42 - $2.17+14.12%Beat13
    2
    5
    30d
    		+177.1%
    Dec 25
    Reported Feb 11
    		$1.88$2.30$2.04 - $2.81-18.26%Miss15
    1
    10
    30d
    		+11.2%
    Sep 25
    Reported Oct 28
    		$2.17$2.07$1.78 - $2.54+4.83%Beat16
    2
    3
    30d
    		+19.9%
    Jun 25
    Reported Jul 30
    		$1.65$1.50$1.34 - $1.80+10.00%Beat15
    1
    3
    30d
    		+1.2%
    Mar 25
    Reported May 5
    		$0.70$1.09$0.15 - $1.65-35.78%Miss14
    1
    10
    30d
    		-41.7%
    Dec 24
    Reported Feb 6
    		$1.69$1.93$0.50 - $2.35-12.44%Miss13
    3
    2
    30d
    		+9.7%
    Sep 24
    Reported Oct 30
    		$1.81$1.82$1.26 - $2.12-0.55%Miss19
    6
    0
    30d
    		+17.5%
    Jun 24
    Reported Aug 1
    		$1.63$1.53$0.27 - $1.71+6.54%Beat17
    3
    0
    30d
    		+30.4%
    Mar 24
    Reported May 1
    		$1.20$1.29$0.18 - $1.77-6.98%Miss18
    6
    4
    30d
    		+335.3%
    Dec 23
    Reported Feb 7
    		$1.54$1.51$0.79 - $1.81+1.99%Beat19
    6
    1
    30d
    		+24.2%

    Key Metrics

    Valuation
    P/E Ratio18.37EV/EBITDA16.87x
    Price/FCF16.16xFCF Yield6.19%
    Profitability
    Profit Margin19.00%Operating Margin32.00%
    ROE20.40%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest Coverage3.85x
    Current Ratio2.04xQuick Ratio1.97x
    Trading Statistics
    Beta0.33Avg Volume1.43M
    52-Week High$186.1252-Week Low$122.14

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$153.05
    SMA 20$146.09
    SMA 50$147.22
    SMA 200$148.02
    EMA 10$154.99
    EMA 20$150.19
    EMA 50$149.26
    EMA 200$148.87

    MACD

    Line: 4.45Signal: 1.65Hist: 2.80

    ADX

    ADX: 26.6+DI: 34.3-DI: 13.6

    Aroon & PSAR

    Aroon Up88.0
    Aroon Down32.0
    PSAR$148.28

    Bollinger Bands

    Upper Band$165.89
    Lower Band$126.30
    %B Position2710%(Upper)
    Band Width0.97

    RSI (14-Day)

    Neutral
    69.4

    Momentum Oscillators

    Stoch %K82.0
    Stoch %D83.1
    Williams %R-15.5
    ROC (10d)15.4%
    Momentum21.93
    CCI (20d)157.1
    MFI (14d)74.3

    Volatility Measures

    ATR (14d)$5.46(3.3%)
    StdDev (20d)9.90
    Hist Vol56.0%(High)

    Volume Flow

    VWAP$163.05
    OBV22.6M
    AD Line5.6M
    CMF (20d)0.096

    Volume Metrics

    Avg Vol (20d)1.5M
    Vol Ratio1.0x
    VWMA (20d)$148.82

    Pivot Points

    R3$173.31
    R2$170.49
    R1$165.13
    Pivot Point$162.31
    S1$156.95
    S2$154.13
    S3$148.77

    Advanced Oscillators

    TSI26.48
    Ultimate Osc60.7
    KST53.62

    Financial Data

    QuarterSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total Revenue$1.12B$959.00M$814.50M$805.50M$794.90M$687.50M$572.60M$627.70M$622.10M$590.20M$515.30M$515.20M
    Cost of Revenue$0$0$13.80M$17.60M$0$10.30M$9.20M$9.30M$8.00M$9.20M$7.50M$8.50M
    Gross Profit$1.12B$959.00M$800.70M$787.90M$794.90M$677.20M$563.40M$618.40M$614.10M$581.00M$507.80M$506.70M
    Operating Expenses$791.40M$807.50M$607.30M$577.00M$555.90M$531.60M$539.80M$476.40M$430.30M$435.60M$408.50M$356.40M
    R&D$363.50M$328.20M$317.40M$275.20M$250.30M$244.30M$263.30M$188.60M$196.00M$193.60M$165.40M$137.50M
    SG&A$366.30M$439.70M$318.50M$301.80M$291.60M$286.30M$276.50M$287.80M$234.30M$242.00M$243.10M$218.90M
    Operating Income$331.30M$151.50M$193.40M$210.90M$239.00M$145.60M$23.60M$142.00M$183.80M$145.40M$99.30M$150.30M
    Interest Income$5.00M$12.40M$28.10M$25.80M$22.20M$0$21.70M$22.50M$23.40M$22.80M$22.30M$17.80M
    Interest Expense$300,000$2.90M$0$0$0$0$8.90M$0$0$49.70M$88.70M$-1,100,000
    Income Before Tax$283.70M$162.20M$246.80M$239.40M$291.80M$159.50M$14.70M$162.60M$190.30M$98.60M$34.50M$198.20M
    Income Tax Expense$77.20M$17.80M$48.90M$85.70M$82.30M$52.00M$6.80M$59.50M$60.50M$33.60M$-8,900,000$50.50M
    Net Income$206.50M$144.40M$197.90M$153.70M$209.50M$107.50M$7.90M$103.10M$129.80M$65.00M$43.40M$147.70M
    EBITDA$329.40M$180.20M$224.70M$219.10M$274.60M$163.40M$-4,000,000$141.60M$166.90M$125.80M$100.00M$178.70M
    EBIT$279.00M$152.70M$218.70M$213.60M$269.60M$159.50M$-7,000,000$140.10M$166.90M$125.50M$100.90M$179.30M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about NBIX

    News

    Adults with uncontrollable movements averaged 5.6 missed work or school days a month before treatment, versus 2.0 after.

    Neurocrine Biosciences announced new survey results showing that adults with tardive dyskinesia (TD) experienced significantly fewer work and school disruptions after starting treatment with INGREZZA. Reported...

    Stock Titan•11/5/26•Neutral

    Neurocrine Biosciences Presents New Tardive Dyskinesia Survey Results Showing Fewer Work and School Disruptions with INGREZZA® (valbenazine) Capsules

    Neurocrine Biosciences announced new survey results showing that adults with tardive dyskinesia (TD) experienced fewer disruptions to work and school...

    PR Newswire•11/5/26•Bullish

    Neurocrine Biosciences, Inc. 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:NBIX) 2026-11-04

    Neurocrine Biosciences, Inc. published their slide deck in conjunction with their 2026 Q3 earnings call. The company reported an EPS of $3.29, beating estimates by $0.54, and revenue of $1.12 billion...

    Seeking Alpha•11/4/26•Neutral

    Neurocrine Biosciences, Inc. Stock 12‑Month Price Target Raised to $209.27, Implies 44% Upside

    The average 12-month price target for Neurocrine Biosciences, Inc. (NBIX) stock has increased to $209.27 from $207.37...

    TradingView•11/3/26•Bullish

    Neurocrine stock rises on Q3 beat, guidance hike (NBIX:NASDAQ)

    Neurocrine Biosciences (NBIX) experienced a significant intraday stock jump of over 15% after reporting strong Q3 2026 results. The rare disease drugmaker exceeded quarterly expectations and raised its guidance...

    Seeking Alpha•11/3/26•Bullish

    NBIX Valuation and Fair Value

    P/E
    18.4x
    Forward P/E
    16.9x
    EV/EBITDA
    16.9x
    P/FCF
    16.2x
    PEG
    0.3x
    P/B
    4.3x
    See GNG's fair value

    NBIX Profitability: Margins, ROIC and FCF

    Gross margin
    99.2%
    Operating margin
    32.0%
    Net margin
    19.0%
    ROE
    20.4%
    FCF margin
    28.0%
    FCF yield
    6.2%

    NBIX Competitors

    CompanyTicker
    Exelixis IncEXEL
    ICON PLCICLR
    Revvity Inc.RVTY
    Charles River LaboratoriesCRL
    Ascendis Pharma ASASND
    Solventum Corp.SOLV
    Hologic IncHOLX
    Jazz Pharmaceuticals PLCJAZZ

    Sector: Healthcare

    NBIX Analyst Ratings

    Consensus
    Buy
    Analysts
    29
    Strong Buy
    4
    Buy
    21
    Hold
    4
    Sell
    0
    Strong Sell
    0

    NBIX Bull Case vs Bear Case

    Bull case

    • NBIX converts 28.0% of revenue into free cash flow.
    • NBIX grew quarterly revenue 41.2% year over year.
    • 86.2% of NBIX's analyst ratings are Buy or Strong Buy.

    NBIX Earnings: Beat Rate and Next Report

    Beat rate
    5 of 8 quarters (62.5%)
    Average surprise
    3.8%
    EPS estimate (fiscal period ending Dec 31, 2026)
    $3.80

    NBIX Earnings Date

    NBIX reports Feb 9, 2027, after the close. The date is estimated.

    NBIX Earnings Call

    The latest NBIX earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    NBIX ETF Holders

    GNG tracks 28 ETFs that hold NBIX. The largest weights:

    1. ERShares Private-Public Crossover ETF (XOVR), 2.53% of the fund
    2. Invesco S&P MidCap Quality ETF (XMHQ), 1.68% of the fund
    3. State Street SPDR S&P Biotech ETF (XBI), 1.35% of the fund
    4. iShares Biotechnology ETF (IBB), 1.02% of the fund
    5. VictoryShares Free Cash Flow ETF (VFLO), 0.82% of the fund
    Open the ETF Stock Exposure tool for NBIX

    See insider activity

    Frequently Asked Questions About NBIX

    When does NBIX report earnings?

    Neurocrine Biosciences Inc (NBIX) is expected to report earnings on Feb 9, 2027.

    Does NBIX pay dividends?

    Neurocrine Biosciences Inc (NBIX) does not currently pay a regular dividend.

    What is NBIX's P/E ratio?

    Neurocrine Biosciences Inc has a price-to-earnings (P/E) ratio of 18.37.

    What is NBIX's market cap?

    Neurocrine Biosciences Inc (NBIX) has a market capitalization of $16.17B with a current stock price of $164.63.

    Related stocks

    Sector: Healthcare

    All stocks starting with N

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In